Compare VHI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHI | FULC |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.3M | 467.8M |
| IPO Year | 1994 | 2019 |
| Metric | VHI | FULC |
|---|---|---|
| Price | $14.09 | $3.64 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $16.38 |
| AVG Volume (30 Days) | 11.6K | ★ 4.2M |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $2,077,000,000.00 | N/A |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $196.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.44 | $2.83 |
| 52 Week High | $20.00 | $15.74 |
| Indicator | VHI | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 32.75 |
| Support Level | $12.74 | $2.83 |
| Resistance Level | $14.54 | $8.18 |
| Average True Range (ATR) | 0.54 | 0.27 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 0.00 | 20.76 |
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.